First Tracks Biotherapeutics Announces $200 Million Private Placement

The financing would issue 6,106,870 common shares, with proceeds intended in part for clinical development of ANB033.

Rhea-AI Summary

First Tracks Biotherapeutics (TRAX) entered into a securities purchase agreement for a private placement expected to raise approximately $200 million. The company agreed to sell 6,106,870 common shares at $32.75 per share to institutional investors. Expected gross proceeds exclude placement agent fees and other expenses.

Closing is expected on October 19, 2026, subject to customary closing conditions. First Tracks intends to use proceeds for general corporate purposes, including clinical development of ANB033, a CD122 antagonist. New and existing investors participated in the placement.

2 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Private placement is expected to raise approximately $200 million in gross proceeds before fees and expenses. 16% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Proceeds are intended in part for clinical development of ANB033, a CD122 antagonist.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.Sale of 6,106,870 common shares at $32.75 per share would dilute existing shareholders.

News Explained

TRAX has separately agreed to register resale, while the share sale remains conditional on closing.

TRAX has agreed to sell 6,106,870 common shares, with closing expected on October 19, 2026 subject to customary conditions; if completed, issuing them would increase the share count and reduce existing holders’ percentage ownership absent offsetting changes.

The shares are unregistered and may not be reoffered or resold in the United States absent registration or an applicable exemption; TRAX has agreed to file an SEC registration statement for resale.

The anticipated gross proceeds of $200 million equal 570.2 days of second-quarter operating cash use at that quarter’s reported rate.

Sources and calculations

• First Tracks Biotherapeutics Announces $200 Million Private Placement (2026-10-15)
• Dilution definition (undated)
• Second-quarter 2026 fundamentals (2026-06-30)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $200,000,000 / ($31,918,000 / 91) = 570.2 days

Argus 15 min delay 12 alerts

+2.08% vs previous close $34.84 last price 2.1x rel. volume Open Argus

Details

Market Reaction – TRAX

$33.56 – $36.31 Day Range

$1.24B Market Cap

On Oct 15, the day this news came out, the latest delayed price for TRAX is 2.08% above the previous close. Our momentum scanner has recorded 12 alerts for this stock so far that day. The latest delayed price is $34.84. Relative volume is elevated at 2.1x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Shares offered: 6,106,870 shares Price per share: $32.75 per share Gross proceeds: Approximately $200 million +1 more

Shares offered

6,106,870 shares

Common stock in the private placement

Price per share

$32.75 per share

Private placement price

Gross proceeds

Approximately $200 million

Before placement agent fees and other expenses

Expected closing

October 19, 2026

Subject to customary closing conditions

Historical Context

1 past event · Latest: Oct 12

1 event

1. Oct 12

   clinical data

   24h Move

   +6.9%

   Phase 1b celiac study reported statistically significant intestinal-damage and symptom benefits for ANB033.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

private placement, securities purchase agreement, registration statement

3 terms

private placement financial

"sell 6,106,870 shares of its common stock to a limited group of institutional investors in a private placement"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

securities purchase agreement financial

"entered into a securities purchase agreement to sell 6,106,870 shares"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

registration statement regulatory

"agreed to file a registration statement with the SEC registering the resale"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 6,106,870 shares of its common stock to a limited group of institutional investors in a private placement at a price of $32.75 per share. First Tracks Biotherapeutics anticipates approximately $200 million in gross proceeds to the company before deducting placement agent fees and other expenses. Closing of the private placement is expected to occur on October 19, 2026, subject to the satisfaction of customary closing conditions.

The private placement included participation from new and existing investors including Affinity Asset Advisors, LLC, First Light Asset Management, Sirenia Capital Management LP, TCGX, Trails Edge Capital Partners, Vestal Point Capital, a life sciences-focused institutional investor and multiple leading mutual funds.

First Tracks Biotherapeutics intends to use the proceeds from the private placement for general corporate purposes, including for clinical development of ANB033, a CD122 antagonist.

Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities are acting as placement agents for the private placement.

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities will not and have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States absent registration or an applicable exemption from registration requirements. First Tracks Biotherapeutics has agreed to file a registration statement with the SEC registering the resale of the common stock sold in the private placement.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: statements relating to the expected timing of closing of the private placement, the intended use of proceeds and the filing of a registration statement. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Investor Contact:
Nick Montemarano
Vice President, Investor Relations
858.732.0178
investors@firsttracksbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is First Tracks Biotherapeutics raising in its private placement, and at what price?

First Tracks expects approximately $200 million in gross proceeds from selling 6,106,870 common shares at $32.75 per share. Gross proceeds are before placement agent fees and other expenses.

When is the First Tracks Biotherapeutics private placement expected to close?

The private placement is expected to close on October 19, 2026, subject to satisfaction of customary closing conditions.